AVAdoración Valiente

Adoración Valiente

*This is an algorithmically generated author record based on publicly available information.

Adoración Valiente has a total of 143 co-authors. Here are the top co-authors by number of shared publications:

  • Elisa Cordero

    Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital/CSIC/University of Seville, 41013 Seville, Spain

    3 shared publications
  • Gabriela Abelenda-Alonso

    Infectious Diseases Department, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Spain

    2 shared publications
  • Javier Sánchez-Céspedes

    Affiliations Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain, CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain

    2 shared publications
  • Jordi Carratalà

    Department of Infectious Diseases, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain

    2 shared publications
  • 3C-Dijon Study

    1 shared publication
  • Adelina Gimeno-Gascón

    Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville , Seville

    1 shared publication

Latest Publications

  • Open Access

    Campylobacter spp Bloodstream Infections in Immunocompetent vs Immunodeficient Patients: A Multinational Cohort Study (2009–2024)

    by María Paniagua-García, José Manuel Bernal-Aznar, Effrossyni Gkrania-Klotsas, Isobel Soper, María Lluisa Pedro-Botet Montoya, Esteban A Reynaga, Adoración Valiente, María Carmen Domínguez-Jiménez, Andrea Lombardi, María Navarro, et al.

    Background: Campylobacter spp bloodstream infections (BSIs) are an emerging clinical challenge, yet information on their clinical features remains limited. We aimed to evaluate their differential clinical characteristics and outcomes in immunocompetent (IC) and immunodeficient (ID) patients. Methods: A multicenter, multinational, retrospective cohort study of consecutive Campylobacter spp BSIs between 2009 and 2024 was carried out. Demographics, Charlson comorbidity index, types of immunodeficiencies, clinical characteristics, and antimicrobial susceptibility were analyzed. The primary outcomes were relapse or reinfection and death (all-cause mortality outcome). Results: A total of 261 episodes were included, 89 (34.1%) in IC and 172 (65.9%) in ID patients. Among the 172 ID patients, 104 (60.5%) and 68 (39.5%) had humoral or nonhumoral immunodeficiency (primary or secondary), and 42 (24.4%) had primary immunodeficiencies (PIDs). Patients with humoral immunodeficiency (humoral-ID patients) were younger (median age, 40 years [interquartile range, 23–66 years]), had lower Charlson comorbidity indexes (2 [1–5]), and had a higher frequency of previous Campylobacter spp infection. Resistance rates to fluoroquinolones (75%) and macrolides (14.5%) were high. BSI relapse or reinfection occurred in 21 (8.0%) patients, mostly humoral-ID patients (n = 19 [18.3%]), 11 (57.9%) of whom had PID. Death occurred with 30 days (all-cause mortality outcome) in 26 patients (9.9%) across the entire cohort; the 30-day mortality rate was lower in humoral-ID (n = 5 [4.8%]) than in IC (n = 12 [13.5%]; P = .05) patients. Conclusions: Humoral-ID patients and those with Campylobacter spp BSI were younger and had fewer comorbid conditions, and Campylobacter coli was the most frequent species. Relapse or reinfection was common in humoral-ID patients, particularly those with PID. The antimicrobial resistance in C coli and Campylobacter jejuni represents a clinical concern.

  • Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

    by Alexander Rombauts, Carmen Infante, Mikel del Álamo Martínez de Lagos, Jorge Alba, Adoración Valiente, Carla Donado-Mazarrón, Marta Carretero-Ledesma, Regino Rodríguez-Álvarez, Sonia Omatos, Zaira R. Palacios-Baena, et al.


  • Open Access

    Autoantibodies against type I IFNs in patients with critical influenza pneumonia

    by Qian Zhang, Andrés Pizzorno, Lisa Miorin, Paul Bastard, Adrian Gervais, Tom Le Voyer, Lucy Bizien, Jeremy Manry, Jérémie Rosain, Quentin Philippot, et al.

    Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.